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Minimally invasive autopsy (MIA) is a validated and safe method to establish the cause of
death (COD), mainly in low-resource settings. However, the additional clinical value of MIA
in Coronavirus disease (COVID-19) patients in a high-resource setting is unknown. The
objective was to assess if and how MIA changed clinical COD and contributing diagnoses in
deceased COVID-19 patients.
Methods and findings
A prospective observational cohort from April to May 2020 in a 981-bed teaching hospital in
the epicenter of the COVID-19 pandemic in Belgium was established. Patients who died
with either PCR-confirmed or radiologically confirmed COVID-19 infection were consecu-
tively included. MIA consisted of whole-body CT and CT-guided Tru-Cut® biopsies. Diag-
nostic modalities were clinical chart review, radiology, microbiology, and histopathology
which were assessed by two independent experts per modality. MIA COD and contributing
diagnoses were established during a multi-disciplinary meeting. Clinical COD (CCOD) and
contributing diagnosis were abstracted from the discharge letter. The main outcomes were
alterations in CCOD and contributing diagnoses after MIA, and the contribution of each diag-
nostic modality. We included 18 patients, of which 7 after intensive care unit hospitalization.
MIA led to an alteration in 15/18 (83%) patients. The CCOD was altered in 5/18 (28%)
patients. MIA found a new COD (1/5), a more specific COD (1/5), a less certain COD (1/5),
or a contributing diagnosis to be the COD (2/5). Contributing diagnoses were altered in 14/
18 (78%) patients: 9 new diagnoses, 5 diagnoses dismissed, 3 made more specific, and 2
made less certain. Overall, histopathology contributed in 14/15 (93%) patients with alter-
ations, radiology and microbiology each in 6/15 (40%), and clinical review in 3/15 (20%).
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Histopathology was deemed the most important modality in 10 patients, radiology in two
patients, and microbiology in one patient.
Conclusion
MIA, especially histological examination, can add valuable new clinical information regard-
ing the cause of death in COVID-19 patients, even in a high-resource setting with wide
access to premortem diagnostic modalities. MIA may provide important clinical insights and




Minimally invasive autopsy (MIA) is a validated tool to establish the cause of death, that has
been studied mainly in resource-limited settings [1]. One of the advantages of MIA is its lim-
ited risk of disease transmission making it an ideal tool in the current coronavirus disease 2019
(COVID-19) pandemic [2, 3]. However, if it increases clinical knowledge in COVID-19
patients in high-resource settings remains unknown. We systematically performed MIA in
deceased COVID-19 patients and assessed to which extent clinically relevant diagnoses
changed, compared to premortem diagnoses.
Methods
This was a prospective observational cohort at Jessa hospital, Hasselt, Belgium. Patients with
either severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reac-
tion (PCR) positivity or radiologically confirmed COVID-19 who died during hospitalization
were consecutively included. Radiologically confirmed COVID-19 was defined as a person in
whom PCR testing for COVID-19 is negative, but in whom the diagnosis is made on the basis
of a suggestive clinical presentation AND a compatible CT-scan, according to the Belgian
national guidelines. The researchers were notified by a mortuary staff member in case of new
eligible patients. Autopsies of all included patients were performed maximally 24 hours after
death. Relevant demographic data (age, sex, comorbidities, admission date and time of death)
were collected from patient’s electronic medical file. Whole body 128-slice CT-scan was per-
formed (Somatom go.top, Siemens Healthcare, Erlangen, Germany) followed by CT-guided
Tru-Cut1 biopsies. Four sterile lung biopsies were taken for microbiological examination and
at least 2 biopsies from heart, lungs, liver, spleen, kidneys and abdominal fat for histological
examination. Additional samples were taken when indicated. Each tissue was stained routinely
with hematoxylin-eosin (H&E) and with ancillary staining when indicated. Lung tissue was
inoculated on standard culture media for bacteria, yeasts and molds and microorganisms were
identified by Matrix-assisted laser desorption ionization–time of flight mass spectrometry.
SARS-CoV-2 real-time-PCR on lung tissue and IgG antibody detection was performed for all
radiologically confirmed COVID-19 patients.
The clinical cause of death (CCOD) and contributing diagnoses were abstracted from the
discharge letter by an independent researcher who was not part of the team of clinical review-
ers. Two clinicians, two radiologists, two microbiologists and two pathologists independently
assessed the clinical files, the postmortem CT-scans, microbiological findings and histology
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slides respectively. The clinical file review included the discharge letter. The other diagnostic
modalities were assessed blinded from the CCOD.
During a multidisciplinary meeting the results of each diagnostic modality were presented,
and the MIA cause of death (MCOD) and contributing diagnoses were formulated in consen-
sus. Furthermore, the contribution of each diagnostic modality (clinical review, radiology,
microbiology and histopathology) was assessed and ranked from most important to least
important, or no contribution, during the meeting. Afterwards, the MCOD and contributing
diagnoses were compared to the CCOD and contributing diagnoses. Alterations in CCOD and
contributing diagnoses were specified. Descriptive statistics were used to report the proportion
of diagnoses that were altered by MIA, how they were altered and how the different modalities
contributed.
Patients were included after oral informed consent was obtained from their legal represen-
tative. Oral consent was documented together with patient and legal representative contact
information in a data file stored on a secured server in the hospital. Written consent of the
legal representative could not be obtained due to visiting restrictions in the hospital during the
pandemic. An information sheet containing the contact details of the researcher was send by
registered mail. The study and the procedure for oral consent received ethical approval from
the Ethics Committee of Jessa hospital and Hasselt University (Clinicaltrials.gov identifier:
NCT 04366882).
Results
We included 18 out of 25 eligible patients (72%) between 14th of April and 12th of May, of
which 15 were PCR SARS-CoV-2 and 3 radiologically confirmed. For the excluded patients,
consent was declined by the legal representative (n = 4) or the legal representative could not be
reached (n = 3). The median (interquartile range [IQR]) age was 80 years (72–84), 10/18 (56%)
patients were male, median (IQR) Charlson Comorbidity index was 3 (1–4) and 12/18 (67%)
patients had a no invasive-ventilation policy. In total 7/18 (39%) patients were admitted to the
ICU at time of death and the median (IQR) time from admission to death was 18 days (5–22).
All but 2 patients had respiratory failure (need for invasive ventilation or PaO2/FiO2 ratio
<300) in the 24 hours preceding death. In the 72 hours before death, 9/18 (50%) patients
received broad-spectrum antibiotics or antifungals and 13/18 (72%) anticoagulants.
In 15/18 (83%) patients, MIA led to an alteration in CCOD or contributing diagnosis: in 5/18
patients the CCOD altered and in 14/18 a contributing diagnosis was changed (Table 1). MIA
revealed the COD in one patient, i.e. radiological COVID-19 with severe pneumonia as CCOD
was dismissed and heart failure revealed as MCOD. CCOD was made more specific in one patient
and less certain in another. In two patients, conditions that were determined clinically as contrib-
uting diagnoses were deemed more relevant by MIA and assigned as the MCOD.
MIA revealed 9 new contributing diagnoses, 5 contributing diagnoses were dismissed after
MIA, 3 made more specific, and 2 made less certain.
For all 3 patients with radiologically confirmed COVID-19 both postmortem serology and
PCR on lung tissue were negative. Two of these patients died of bacterial pneumonia and heart
failure respectively, and the diagnosis COVID-pneumonia was completely dismissed. For the
third patient, MIA concluded an unspecified viral pneumonia as MCOD. When considering
only PCR confirmed COVID-19 patients, MIA led to an alteration in 12/15 (80%) patients: in
3/15 patients the CCOD was altered and in 12/15 a contributing diagnosis was changed.
Bacterial pneumonia as clinical contributing diagnosis was dismissed in 3 patients and
made less certain in one. Overall, MIA found bacterial or fungal pneumonia as relevant diag-
nosis in only 2/18 (11%) patients.
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Clinical COD Clinical contributing
diagnoses
MIA COD MIA contributing
diagnoses
MIA alteration
PCR confirmed COVID-19 patients
1 21 Yes COD Rabdomyolysis with subsequent MOF
including renal failure with dialysis
Rabdomyolysis eci with subsequent





COVID-19 severe pneumonia clinically
improving
COVID-19 severe pneumonia Confirm
2 51 Yes COD Sudden death eci Sudden death eci Confirm
44 Yes Contributing
diagnoses





Minor intracerebral bleeding New
Sepsis New







COVID-19 severe pneumonia More specific
Bacterial co-infection highly suspected Dismiss





Massive pulmonary embolism COVID-19 severe pneumonia Confirm
Hepatitis eci Right sided heart failure leading to
severe sinusoidal dilatation in the
liver
More specific
5 Unkown Yes COD Intracerebral bleeding Intracerebral bleeding Confirm
20 Yes Contributing
diagnoses
Renal failure eci leading to dialysis Renal failure due to ATN leading to
dialysis
More specific
COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
Steatohepatitis New
6 27 No COD COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
17 No Contributing
diagnoses
Acute on chronic renal failure No renal biopsy performed -
Left-and right sided heart failure New
Subileus New
7 18 No COD Probable invasive Aspergillus fumigatus
pulmonary infection





COVID-19 severe pneumonia Probable invasive Aspergillus
fumigatus pulmonary infection
Less certain
Cerebral B-cell lymphoma Cerebral B-cell lymphoma Confirm
8 Unkown No COD Small cell lung carcinoma with
metastasis





COVID-19—mild illness COVID-19—mild illness Confirm
Pancreatitis eci New
9 3 No COD COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
1 No Contributing
diagnoses
Bacterial COPD excacerbation Dismiss
10 18 Yes COD Intracranial bleeding with subdural
hematoma
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When assessing the 15 patients in which MIA contributed to the final diagnoses, histopa-
thology contributed in 14/15 (93%) patients, radiology and microbiology each in 6/15 (40%)
patients, and clinical review in 3/15 (20%) patients. When ranked according to contribution,








Clinical COD Clinical contributing
diagnoses





COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
11 32 Yes COD Para-tracheal bleeding eci while on
anticoagulant therapy for DVT and AF
Para-tracheal bleeding eci while on





COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
12 28 Yes COD COVID-19 severe pneumonia COVID-19 severe pneumonia Confirm
24 No Contributing
diagnoses
Hospital acquired pneumonia Hospital acquired pneumonia Less certain
13 Unkown No COD Hemorrhagic and semi recent ischemic
cerebrovascular accident





Depression with refusal of food and
medical interventions
Depression with refusal of food and
medical interventions
Confirm
COVID-19—mild illness COVID-19—mild illness Confirm
Bacterial pneumonia New
14 Unkown Yes COD COVID-19 pneumonia COVID-19 pneumonia Confirm
22 No Contributing
diagnoses
Hospital acquired pneumonia Dismiss
Left- and right sides heart failure New
15 12 No COD COVID-19 Pneumonia COVID-19 Pneumonia Confirm
65 No Contributing
diagnoses





Hospital acquired pneumonia Dismiss
Radiologivally confirmed COVID-19 patients
16 Unkown No COD Radiological COVID-19 severe
pneumonia with negative SARS-CoV-2
PCR
Left-and right sided heart failure Dismiss/New
6 No Contributing
diagnoses
Pseudoaneurysma left femoral artery Pseudoaneurysma left femoral artery Confirm
17 1 No COD Radiological COVID-19 severe
pneumonia with negative SARS CoV-2
PCR
Viral pneumonia Less certain
1 No Contributing
diagnoses
Left- and right sided heart failure New
18 11 No COD Bacterial Pneumonia Bacterial pneumonia Confirm
1 No Contributing
diagnoses
Left- and right sided heart failure Left- and right sided heart failure Confirm
Radiological COVID-19 severe
pneumonia with negative SARS CoV-2
PCR considered
Dismiss
Per patient, the COD is the first diagnosis given. Following diagnoses are contributing findings. eci: e causa ignota; MOF: multi-organ failure; COVID-19: corona viral
disease 2019; ATN: acute tubules necrosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; PCR: polymerase chain reaction; COPD: chronic obstructive
pulmonary diseases; DVT: deep venous thrombosis; AF: atrial fibrillation
https://doi.org/10.1371/journal.pone.0242300.t001
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was ranked first in 2 patients, and microbiology in 1 patient. In 2 patients, each modality con-
tributed equally.
Discussion
MIA led to alterations in CCOD and contributing clinical diagnoses in 83% of deceased
patients with either PCR-confirmed (15 patients) or radiologically confirmed (3 patients)
COVID-19. Ten clinically relevant diagnoses were revealed. These included heart failure (four
times), sepsis, and bacterial pneumonia, i.e. diagnoses that might have influenced clinical treat-
ment when known premortem. In all patients with radiologically confirmed COVID-19,
SARS-CoV-2 infection could not be confirmed with postmortem PCR or serology.
In 2/3 radiologically confirmed COVID-19 patients, MIA dismissed the diagnosis of
COVID-19 altogether, and in one, it made COVID-19 very unlikely. These were patients that
were isolated and treated as COVID-19 patients, in line with the Belgian national guidelines
[4]. International guidelines also include patients with typical chest findings as probable
COVID-19 cases, as PCR testing for SARS-CoV-2 does not have 100% sensitivity [5, 6].
Although we included only 3 radiological COVID-19 patients, our results confirm the lack of
specificity for COVID-19 on CT-scans [7] and emphasize the need for clinicians to remain
alert in these cases, even amid a pandemic, and consider alternative diagnoses [7].
Overall, MIA found histopathological or microbiological evidence of bacterial or fungal
superinfection in 11% of patients, yet 50% of patients were on antibiotic and/or antifungal
treatment in the 72 hours before death. Even though MIA results could have been negatively
influenced by concurrent antimicrobial treatment or sampling error (although sampling was
done by CT-guidance), this observation is in line with others reporting low prevalence of co-
infections [8–11]. This is of relevance as antimicrobial overuse leads to resistance, toxicity and
unnecessary costs.
Histopathology was the diagnostic modality within MIA that most often contributed to the
final conclusion, and therefore considered the most relevant part of MIA. Radiology was
found to have less impact. This may be partly explained by the fact that 6/18 (33%) of patients
had a CT-scan 48 hours prior to death, showing relevant findings in all six. Therefore, if CT-
scanning was not as widely available premortem, it would have had a higher postmortem
yield.
Inherent to its technique, MIA may not be able to detect all clinically relevant findings. For
example, for pulmonary embolism—an important complication in COVID-19 patients [12,
13]—MIA has insufficient sensitivity. Therefore, complete autopsies remain the gold standard
to establish the COD. However, complete autopsy rates have been decreasing in high-income
setting over the last decades [14], with likely simultaneous loss of expertise and facilities to per-
form complete autopsies. Moreover, acceptance of MIA by relatives may be higher when com-
pared to complete autopsy [1]. Lastly, in the beginning of the COVID-19 pandemic, there was
uncertainty about the safety of performing complete autopsies and reluctance to perform them
[3, 15, 16]. Therefore, we think MIA should be viewed as an additional method to gain clini-
cally relevant insights, especially when complete autopsies are not feasible.
One of the strengths of this study is the prospective and consecutive inclusion of patients
for autopsy, and thus the absence of selection based on disease severity. On the other hand,
this study has some limitations. First, sampling was limited to certain organs, e.g. we found in
33% of our patients relevant radiological abnormalities in the brain but because the brain was
not biopsied, a more precise diagnosis could not be made. Second, some patients had treat-
ment restrictions during admission, limiting diagnostic and therapeutic management during
life, which may have biased our findings. Furthermore, discharge letters may not provide the
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complete clinical picture premortem, although the postmortem clinical file review only con-
tributed to the MIA final diagnosis in 3/18 patients. Lastly, the distinction between COD and
contributing diagnosis is often artificial. Patients die as a result of a cascade of events, influ-
enced by numerous external factors. A list of diagnoses cannot simply reflect the disease com-
plexity [17].
Our study shows that MIA adds clinically relevant information on COD and contributing
diagnoses in COVID-19 patients in a majority of patients, also in a high-technological setting.
More accurate diagnoses provide a better knowledge on what diseases eventually cause death
in COVID-19 patients and informs and improves future care. For that purpose, MIA can be
applied in the current ongoing pandemic.
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